Pfizer’s Prevnar 13 Is Approved For Older Children As Use In Adults Lags

FDA approved use of the pneumococcal vaccine in children and adolescents aged six to 17 years; uptake in adults 50 and older has been impacted by the delay in getting an ACIP vote on treatment, which is expected later this year.